vs
Primerica, Inc.（PRI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Primerica, Inc.的季度营收约是Royalty Pharma plc的1.4倍（$853.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 23.1%，领先11.4%），Primerica, Inc.同比增速更快（11.0% vs 4.8%），过去两年Primerica, Inc.的营收复合增速更高（7.2% vs 4.6%）
Primerica, Inc.是一家采用多层次营销模式的金融服务机构，业务覆盖美国与加拿大市场，主要面向当地中等收入家庭提供保险、投资等多元化金融产品，满足客户的风险保障与差异化财富管理需求。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PRI vs RPRX — 直观对比
营收规模更大
PRI
是对方的1.4倍
$622.0M
营收增速更快
PRI
高出6.3%
4.8%
净利率更高
RPRX
高出11.4%
23.1%
两年增速更快
PRI
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $853.7M | $622.0M |
| 净利润 | $197.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 28.9% | 62.4% |
| 净利率 | 23.1% | 34.4% |
| 营收同比 | 11.0% | 4.8% |
| 净利润同比 | 17.9% | 2.9% |
| 每股收益（稀释后） | $6.11 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRIRPRX
| Q4 25 | $853.7M | $622.0M | ||
| Q3 25 | $839.9M | $609.3M | ||
| Q2 25 | $793.3M | $578.7M | ||
| Q1 25 | $804.8M | $568.2M | ||
| Q4 24 | $768.8M | $593.6M | ||
| Q3 24 | $774.1M | $564.7M | ||
| Q2 24 | $803.4M | $537.3M | ||
| Q1 24 | $742.8M | $568.0M |
净利润PRIRPRX
| Q4 25 | $197.0M | $214.2M | ||
| Q3 25 | $206.8M | $288.2M | ||
| Q2 25 | $178.3M | $30.2M | ||
| Q1 25 | $169.1M | $238.3M | ||
| Q4 24 | $167.1M | $208.2M | ||
| Q3 24 | $164.4M | $544.0M | ||
| Q2 24 | $1.2M | $102.0M | ||
| Q1 24 | $137.9M | $4.8M |
毛利率PRIRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 98.0% | — | ||
| Q1 24 | 98.2% | — |
营业利润率PRIRPRX
| Q4 25 | 28.9% | 62.4% | ||
| Q3 25 | 32.3% | 70.1% | ||
| Q2 25 | 29.6% | 36.3% | ||
| Q1 25 | 27.5% | 94.0% | ||
| Q4 24 | 64.7% | 60.9% | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 1.0% | 50.2% | ||
| Q1 24 | 24.1% | -13.0% |
净利率PRIRPRX
| Q4 25 | 23.1% | 34.4% | ||
| Q3 25 | 24.6% | 47.3% | ||
| Q2 25 | 22.5% | 5.2% | ||
| Q1 25 | 21.0% | 41.9% | ||
| Q4 24 | 21.7% | 35.1% | ||
| Q3 24 | 21.2% | 96.3% | ||
| Q2 24 | 0.1% | 19.0% | ||
| Q1 24 | 18.6% | 0.8% |
每股收益（稀释后）PRIRPRX
| Q4 25 | $6.11 | $0.49 | ||
| Q3 25 | $6.35 | $0.67 | ||
| Q2 25 | $5.40 | $0.07 | ||
| Q1 25 | $5.05 | $0.55 | ||
| Q4 24 | $4.92 | $0.46 | ||
| Q3 24 | $4.83 | $1.21 | ||
| Q2 24 | $0.03 | $0.23 | ||
| Q1 24 | $3.93 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $756.2M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.4B | $9.7B |
| 总资产 | $15.0B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PRIRPRX
| Q4 25 | $756.2M | $618.7M | ||
| Q3 25 | $644.9M | $938.9M | ||
| Q2 25 | $621.2M | $631.9M | ||
| Q1 25 | $625.1M | $1.1B | ||
| Q4 24 | $687.8M | $929.0M | ||
| Q3 24 | $550.1M | $950.1M | ||
| Q2 24 | $627.3M | $1.8B | ||
| Q1 24 | $593.4M | $843.0M |
总债务PRIRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PRIRPRX
| Q4 25 | $2.4B | $9.7B | ||
| Q3 25 | $2.3B | $9.6B | ||
| Q2 25 | $2.3B | $9.5B | ||
| Q1 25 | $2.3B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $1.9B | $10.3B | ||
| Q2 24 | $2.1B | $9.8B | ||
| Q1 24 | $2.2B | $9.9B |
总资产PRIRPRX
| Q4 25 | $15.0B | $19.6B | ||
| Q3 25 | $14.8B | $19.3B | ||
| Q2 25 | $14.8B | $18.3B | ||
| Q1 25 | $14.6B | $17.6B | ||
| Q4 24 | $14.6B | $18.2B | ||
| Q3 24 | $14.8B | $18.0B | ||
| Q2 24 | $14.6B | $17.7B | ||
| Q1 24 | $14.9B | $16.1B |
负债/权益比PRIRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $338.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.72× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PRIRPRX
| Q4 25 | $338.2M | $827.1M | ||
| Q3 25 | $202.9M | $702.6M | ||
| Q2 25 | $162.6M | $364.0M | ||
| Q1 25 | $197.5M | $596.1M | ||
| Q4 24 | $270.6M | $742.5M | ||
| Q3 24 | $207.3M | $703.6M | ||
| Q2 24 | $173.3M | $658.2M | ||
| Q1 24 | $210.9M | $664.6M |
现金转化率PRIRPRX
| Q4 25 | 1.72× | 3.86× | ||
| Q3 25 | 0.98× | 2.44× | ||
| Q2 25 | 0.91× | 12.06× | ||
| Q1 25 | 1.17× | 2.50× | ||
| Q4 24 | 1.62× | 3.57× | ||
| Q3 24 | 1.26× | 1.29× | ||
| Q2 24 | 147.98× | 6.45× | ||
| Q1 24 | 1.53× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
